| Name | Title | Contact Details |
|---|
As a pioneer in the development of automated validation software solutions, ValGenesis leads the way with a unique paperless validation process that tracks the validation status of any GxP system in real time. With years of development and refinement in place, ValGenesis is the first to offer users real-time paperless validation via electronic execution thereby minimizing ineffectiveness and maximizing efficiency. ValGenesis automates and manages the validation life cycle and provides real time validation status of any system corporate wide.
Project Farma is a patient-focused global leader in advancing technical operations from ideation through commercialization with a proven track record of planning, building, and maintaining manufacturing facilities, capital expansions, and technical operations for complex biologics and novel modalities. We provide end-to-end services for the entire manufacturing lifecycle for pharmaceutical and biotech companies, universities, hospitals, and government agencies. Project Farma has executed 100+ facility builds, retrofits and expansions, managed 400+ large scale capital projects, industrialized 10+ commercial cell, gene, and novel therapies, and managed $6B+ in technical operations capital investments. One of our core values is giving back. Volunteering at hospitals, supporting life science related fundraisers and partnering with nonprofit organizations is an integral part of our culture. In doing so, not only do we raise awareness of many life-threatening diseases, but we also bring our team and our clients team closer to the actual patients and families that will be impacted by our work. Project Farma is a PerkinElmer company. (https://www.projectfarma.com/)
CINDE Journal is a Hamilton, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Kinnate Biopharma Inc. is a clinical-stage precision oncology company focused on expanding on the promise of targeted therapies for those battling cancer. The company is developing medicines for known oncogenic drivers where there are no approved targeted drugs and to overcome the limitations of marketed cancer therapies, such non-responsiveness or acquired and intrinsic resistance. Kinnate has two lead clinical programs being studied in solid tumors with RAF, NRAS and FGFR-driven alterations, and is rapidly progressing a pipeline of additional small molecule drug candidates as part of the Kinnate Discovery Engine.
Custom Biogenic Systems is a Romeo, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.